^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

LCB84

i
Company:
J&J, LigaChem Biosci, Mediterranea Theranostic
Drug class:
Microtubule inhibitor, TROP-2-targeted antibody-drug conjugate
Related drugs:
1year
LegoChem Biosciences Selects BostonGene as Genomic Partner for First-in-Human Clinical Trial (Businesswire)
"BostonGene...announced a collaboration to support the Phase I/II study of LCB84, a TROP2-directed ADC, in patients with advanced cancers. This first-in-human study is being conducted at leading cancer institutions in the US and Canada to evaluate the safety and preliminary efficacy of LCB84, both as a single-agent therapy and in combination with an immune checkpoint inhibitor (anti-PD-1 antibody)....BostonGene will serve as the study’s central laboratory and analytic partner for exploratory biomarkers, performing in-depth, multi-omic profiling of patients’ tumor tissue and blood samples, including whole-exome sequencing (WES), whole-transcriptome sequencing (RNAseq) of tumor tissue from matched tumor biopsies on the study, and immunoprofiling to identify hundreds of different cell types from a single blood sample."
Licensing / partnership
|
LCB84
1year
Enrollment open • Combination therapy • Metastases
|
LCB84
over1year
New P1/2 trial • Combination therapy • Metastases
|
LCB84